What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “BHV-1510 will be administered on Day 1 and Day 8 every 3 weeks”In the company’s words, NCT06384807 on ClinicalTrials.gov
- Tested for
- Solid Tumor
- Main trialPhase 1/2
- “This is a Phase 1/2, first in human (FIH), open-label, multicenter study of BHV-1510 monotherapy and in Combination with Cemiplimab in participants with previously treated, advanced solid tumors.”In the company’s words, NCT06384807 on ClinicalTrials.gov
- Other names
- PBI-410 · GQ1010
Other drugs for Solid Tumor
- AvelumabEMD Serono Research & Development Institute, Inc. · Phase 3
- AlectinibRoche · Phase 3
- AtezolizumabRoche · Phase 3
- AU-011Aura Biosciences · Phase 3
- BevacizumabRoche · Phase 3
- CadonilimabAkeso · Phase 3
Coming up1
- Feb 2028Phase 1/2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1/2Recruiting | Feb 2028 | A Phase 1/2 Study of BHV-1510 (Previously PBI-410) in Advanced Solid Tumors |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026